These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2014824)

  • 1. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer.
    Berek JS; Chung C; Kaldi K; Watson JM; Knox RM; Martínez-Maza O
    Am J Obstet Gynecol; 1991 Apr; 164(4):1038-42; discussion 1042-3. PubMed ID: 2014824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer.
    Plante M; Rubin SC; Wong GY; Federici MG; Finstad CL; Gastl GA
    Cancer; 1994 Apr; 73(7):1882-8. PubMed ID: 8137215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.
    Rubin SC; Hoskins WJ; Hakes TB; Markman M; Reichman BS; Chapman D; Lewis JL
    Am J Obstet Gynecol; 1989 Mar; 160(3):667-71. PubMed ID: 2648838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 serum levels in patients with gynecological tumors.
    Scambia G; Testa U; Panici PB; Martucci R; Foti E; Petrini M; Amoroso M; Masciullo V; Peschle C; Mancuso S
    Int J Cancer; 1994 May; 57(3):318-23. PubMed ID: 8168990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum evaluation of interleukin 6 in ovarian cancer patients.
    Tempfer C; Zeisler H; Sliutz G; Haeusler G; Hanzal E; Kainz C
    Gynecol Oncol; 1997 Jul; 66(1):27-30. PubMed ID: 9234916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
    Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
    Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients.
    Hurteau JA; Simon HU; Kurman C; Rubin L; Mills GB
    Am J Obstet Gynecol; 1994 Mar; 170(3):918-28. PubMed ID: 8141226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.
    Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ
    Eur Cytokine Netw; 2013; 24(3):106-13. PubMed ID: 24197277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures.
    Watson JM; Sensintaffar JL; Berek JS; Martínez-Maza O
    Cancer Res; 1990 Nov; 50(21):6959-65. PubMed ID: 2208162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
    Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
    Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
    J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
    Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
    Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.
    Makar AP; Kristensen GB; Kaern J; Børmer OP; Abeler VM; Tropé CG
    Obstet Gynecol; 1992 Jun; 79(6):1002-10. PubMed ID: 1579296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of post chemotherapy serum CA 125 in epithelial ovarian cancer.
    Teeling M; McGing P; Carney DN
    Ir J Med Sci; 1989 Mar; 158(3):59-62. PubMed ID: 2745033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevation of multiple serum markers in patients with stage I ovarian cancer.
    Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
    J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients.
    Huo J; Hu J; Liu G; Cui Y; Ju Y
    Arch Gynecol Obstet; 2017 Feb; 295(2):459-465. PubMed ID: 27975129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the CA 125 assay in the management of ovarian cancer.
    Niloff JM
    Oncology (Williston Park); 1988 Aug; 2(8):67-76. PubMed ID: 3275060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer.
    Kobayashi H; Terao T; Kawashima Y
    J Clin Oncol; 1992 Jan; 10(1):95-101. PubMed ID: 1727929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the monoclonal antibody OC 125 to diagnose malignant ovarian tumors.
    Li XG; Chen DX; Schwartz PE; Yang Z
    Gynecol Oncol; 1989 Mar; 32(3):327-30. PubMed ID: 2920953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.